Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1
Inclisiran works differently from other LDL-C-lowering therapies by harnessing the intrinsic process of RNAi to increase hepatic LDL-C uptake and reduce LDL-C levels in the bloodstream.1-3
Watch the video below to learn more about the mechanism of action of inclisiran.
Multiple factors explain the sustained duration of effect of inclisiran:
Learn more about the inclisiran clinical trial data
For further information please refer to the Summary of Product Characteristics by clicking here
LDL-C, low-density lipoprotein cholesterol; mRNA, messenger ribonucleic acid; RISC, RNA-induced silencing complex; RNAi, ribonucleic acid interference; siRNA, small interfering ribonucleic acid.
Leqvio® Summary of Product Characteristics.
Stoekenbroek RM et al. Future Cardiol 2018;14(6):433–442.
Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.
Khvorova A. N Engl J Med 2017;376(1):4–7.
Fitzgerald K et al. N Engl J Med 2017;376(1):41–51.